论文部分内容阅读
1997年5月28～3O日,约200名疫苗研究工作者出席,由国际生物标准化协会在巴黎Pasteur研究所召开的会议.会议主要讨论了制品进入Ⅰ期临床试验的标准以及临床开发(包括安全性、免疫原性和效力验证)的适当程序.
Approximately 200 vaccine researchers attended the 28-30 May 1997 meeting of the International Association for Biological Standardization (PASB) at the Pasteur Institute in Paris, where they discussed the criteria for entry of Phase I clinical trials and the clinical development (including safety Sexual, immunogenicity and efficacy verification).